FDA Approves Tofacitinib for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
An international panel of pediatric rheumatologists created a new score to address a lack in the 4-item JADAS in quantifying the burden of extra-articular manifestations of juvenile idiopathic arthritis.
Researchers evaluated the use and performance of genomic risk scores for the clinical diagnosis of juvenile idiopathic arthritis.
Severe disease and death appear to be rare among children and young people hospitalized with laboratory-confirmed COVID-19.
Prevalence of SARS-CoV-2 in asymptomatic children linked to incidence of COVID-19 in general population.
Type 2 diabetes may negatively impact bone density around the age of peak bone mass.
Adding corticosteroids to initial IV immunoglobulin may reduce risk for coronary artery abnormalities.
Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.
Researchers characterized the blood gene signatures of male and female patients with systemic juvenile idiopathic arthritis.
Children in England had low positivity rates of SARSCoV2 during the first COVID-19 pandemic peak and also had a low case-fatality rate.